Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 mass balance and pharmacokinetics study of oral 14C-PTC299 in healthy male volunteers
NL-OMON50826Phase 1Active, not recruiting
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of emvododstat in acute myeloid leukemia (AML) and coronavirus disease 2019 (COVID-19), sponsored by PTC Therapeutics, Inc. Primary endpoints: Rates and routes of excretion and mass balance of total radioactivity, Pharmacokinetics of total radioactivity in plasma pools on Day 6 and 1 more. Started Feb 2021; status: active, not recruiting.
02
Drugs
emvododstat
03
Conditions
acute myeloid leukemia (AML)coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON50826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50826.